Supplementary materials for "The Benefit of Taxane-Based Therapies Over Fluoropyrimidine Plus Platinum (FP) in the Treatment of Esophageal Cancer: A meta-analysis of clinical studies".

Table S1 Quality scores of cohort studies.

Table S2 Comparisons of all outcomes in curative effects.

Table S3 Comparisons of grade 3/4 adverse events.

Figure S1 A: Quality assessment of cohort studies; B: Risk of bias graph for randomized controlled trails (RCTs); C: Risk of bias summary for RCTs.

Figure S2 Funnel plots of Begg’s and Egger’s tests. A: Begg’s test for pathological complete response (pCR) in the subgroup of neoadjuvant chemoradiotherapy (NACRT); B: Egger’s test for pCR in the subgroup of NACRT.

Figure S3 Analyses of side effects between taxane-based neoadjuvant chemotherapy (NACT) and fluoropyrimidine plus platinum (FP) based NACT in esophageal cancer (EC). A: grade 3/4 anemia; B: grade 3/4 leukopenia; C: grade 3/4 neutropenia; D: grade 3/4 thrombocytopenia; E: grade 3/4 anorexia; F: grade 3/4 nausea; G: grade 3/4 vomiting; H: grade 3/4 diarrhea.

Figure S4 Analyses of side effects between taxane-based definitive chemoradiotherapy (dCRT) and FP based dCRT in EC. A: grade 3/4 anemia; B: grade 3/4 leukopenia; C: grade 3/4 neutropenia; D: grade 3/4 thrombocytopenia; E: grade 3/4 anorexia; F: grade 3/4 nausea; G: grade 3/4 vomiting; H: grade 3/4 diarrhea; I: grade 3/4 esophagitis; J: grade 3/4 pneumonia.

Figure S5 Analyses of incidence rates of grade 3/4 toxicities in the taxane group in esophageal cancer (EC). A: leukopenia; B: neutropenia; C: diarrhea; D: pneumonia.

Figure S6 Analyses of treatment-related deaths between the taxane group and FP group.

Figure S7 Analyses of incidence rates of grade 3/4 toxicities in taxane-based neoadjuvant therapy (NACT) and taxane-based neoadjuvant chemoradiotherapy (NACRT) in esophageal cancer (EC). A: leukopenia in the subgroup of NACT; B: neutropenia in the subgroup of NACT; C: leukopenia in the subgroup of NACRT; D: neutropenia in the subgroup of NACRT.